This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Bionano Genomics Gestion

Gestion contrôle des critères 2/4

Bionano Genomics' CEO is Robert Holmlin, appointed in Jan 2011, has a tenure of 12.83 years. total yearly compensation is $2.77M, comprised of 19.7% salary and 80.3% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth €66.79K. The average tenure of the management team and the board of directors is 1.8 years and 4.5 years respectively.

Informations clés

Robert Holmlin

Directeur général

US$2.8m

Rémunération totale

Pourcentage du salaire du PDG	19.7%
Durée du mandat du directeur général	12.8yrs
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	1.8yrs
Durée moyenne du mandat des membres du conseil d'administration	4.5yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Robert Holmlin a-t-elle évolué par rapport aux bénéfices de Bionano Genomics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2023	n/a	n/a	-US$147m
Mar 31 2023	n/a	n/a	-US$140m
Dec 31 2022	US$3m	US$544k	-US$133m
Sep 30 2022	n/a	n/a	-US$117m
Jun 30 2022	n/a	n/a	-US$106m
Mar 31 2022	n/a	n/a	-US$92m
Dec 31 2021	US$8m	US$484k	-US$72m
Sep 30 2021	n/a	n/a	-US$61m
Jun 30 2021	n/a	n/a	-US$51m
Mar 31 2021	n/a	n/a	-US$41m
Dec 31 2020	US$708k	US$376k	-US$41m
Sep 30 2020	n/a	n/a	-US$37m
Jun 30 2020	n/a	n/a	-US$33m
Mar 31 2020	n/a	n/a	-US$32m
Dec 31 2019	US$899k	US$404k	-US$30m
Sep 30 2019	n/a	n/a	-US$28m
Jun 30 2019	n/a	n/a	-US$27m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$3m	US$390k	-US$18m
Sep 30 2018	n/a	n/a	-US$18m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$22m
Dec 31 2017	US$605k	US$379k	-US$23m

Rémunération vs marché: Robert's total compensation ($USD2.77M) is above average for companies of similar size in the German market ($USD418.12K).

Rémunération et revenus: Robert's compensation has been consistent with company performance over the past year.

PDG

Robert Holmlin (55 yo)

12.8yrs

Titularisation

US$2,766,572

Compensation

Dr. Robert Erik Holmlin, Ph D., M.B.A. has been the Chief Executive Officer and President of BioNano Genomics, Inc. (alternatively BioNanomatrix, Inc.) since January 12, 2011 and serves as its Secretary. D...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Robert Holmlin	President	12.8yrs	US$2.77m	0.14% € 66.8k
Mark Oldakowski	Chief Operating Officer	6yrs	US$1.50m	0.47% € 232.2k
Alka Chaubey	Chief Medical Officer	3.3yrs	US$1.32m	0.0013% € 625.6
Gulsen Kama	Chief Financial Officer	less than a year	pas de données	pas de données
Mark Adamchak	VP of Accounting & Controller	5.4yrs	pas de données	pas de données
Jonathan Dixon	General Counsel	1.8yrs	pas de données	0.010% € 5.1k
Stanislas Marin	Vice President of Global Sales	1.8yrs	pas de données	pas de données
Donna Polizio	Global Head of Market Access	less than a year	pas de données	pas de données
Cory Kreeck	Global Head of People Operations	1.8yrs	pas de données	pas de données

1.8yrs

Durée moyenne de l'emploi

49.5yo

Âge moyen

Gestion expérimentée: 2Y30's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Robert Holmlin	President	12.8yrs	US$2.77m	0.14% € 66.8k
Christopher Twomey	Independent Director	5.3yrs	US$224.42k	0.017% € 8.4k
David Barker	Independent Chairman of the Board	13.5yrs	US$249.42k	0.015% € 7.6k
Albert Luderer	Independent Director	12.1yrs	US$229.42k	0% € 0
Hannah Mamuszka	Independent Director	3.5yrs	US$211.92k	0.017% € 8.6k
Kristiina Vuori	Independent Director	4.5yrs	US$221.92k	0% € 0
Yvonne Linney	Independent Director	3.5yrs	US$209.42k	0% € 0
Vincent Wong	Independent Director	1.9yrs	US$214.42k	0% € 0
Aleksandar Rajkovic	Independent Director	1.8yrs	US$451.18k	0% € 0

4.5yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Conseil d'administration expérimenté: 2Y30's board of directors are considered experienced (4.5 years average tenure).

This company listing is no longer active

Bionano Genomics Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Bionano Genomics, Inc., Annual General Meeting, Jun 18, 2024

Bionano Genomics, Inc. Announces Executive Changes

Bionano Genomics, Inc. Announces Resignation of Richard Shippy as Chief Business Officer

Bionano Genomics, Inc. Appoints Donna Polizio as Global Head of Market Access

High number of new directors

High number of new directors

Recent updates

Bionano Genomics, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2024

Bionano Genomics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Bionano Genomics, Inc. Announces Publication of First Multi-Site Study to Analyze the Utility of OGM in Multiple Myeloma

Bionano Genomics Receives Non-Compliance Letter from the Nasdaq Stock Market

Bionano Genomics, Inc. has completed a Follow-on Equity Offering in the amount of $9.994188 million.

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000001 million.

Bionano Genomics, Inc. Provides Revenue Guidance for the Second Quarter of 2024 and Reiterated Revenue Guidance for the Year 2024

Bionano Genomics, Inc., Annual General Meeting, Jun 18, 2024

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000002 million.

Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations in Sarcoma Samples That May Lead to Improved Diagnosis But Were Missed by Classical Cytogenetics

Bionano Genomics, Inc. Announces Nine Poster Presentations and Introduces New High Throughput Stratys System at American Association for Cancer Research Annual Meeting

Bionano Genomics, Inc. Announces Publication of Breast Cancer Study Showing the Number of SVs Detected with OGM May be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Bionano Genomics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Bionano Genomics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Bionano Genomics, Inc. announced that it has received $35 million in funding

Bionano Genomics, Inc. Announces Publication of A Study That Applied Ogm to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer

Bionano Announces Full Commercial Release of the Stratys™? System for High Throughput Optical Genome Mapping

Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care in Genetic Disease Testing

Bionano Genomics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Bionano Announces Significant Upgrades to Its Bionano Solve Pipeline and Its Via™ Software for Ogm Data Analysis in Constitution Genetic Disease Research

Bionano Genomics, Inc. Reiterates Revenue Guidance for the Full Year 2023

Bionano Genomics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Bionano Genomics, Inc. announced that it expects to receive $35 million in funding

Bionano Genomics, Inc. announced that it expects to receive $35 million in funding

Bionano Genomics, Inc. Announces the Publication of Study Detailing the Challenges Associated with the Detection and Interpretation of Causal Variants in Mendelian Disease

Bionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Bionano Genomics, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$1.24 loss per share (vs US$1.13 loss in 2Q 2022)

Bionano Genomics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Bionano Genomics, Inc. Announces the Stratys System for OGM and VIA™? Software for Hematologic Malignancies

Bionano Genomics, Inc.(NasdaqCM:BNGO) dropped from Russell Small Cap Comp Value Index

Bionano Genomics, Inc. Announces Peer-Reviewed Publication on the Utility of Combining Ogm and A 523-Gene Ngs Panel for Standard Evaluation of Myeloid Cancers

Bionano Announces Commercial Release of New Kits for Its Ionic System Featuring New Chemistry for Nucleic Acid Extraction from Ffpe and Tumor Tissue

Bionano Genomics Receives Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with Minimum Bid Price Requirement

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.10 loss in 1Q 2022)

Bionano Genomics, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.26 loss in FY 2021)

Bionano Genomics, Inc. Launches Next-Generation Versions of Its Reagent Kits and Chip Consumable, Along with Updates to Its Instrument Control and Bionano Access Software for the Optical Genome Mapping Workflow

Bionano Genomics, Inc. Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing

Bionano Genomics, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Bionano Genomics, Inc. Announces Publication of Study Utilizing Optical Genome Mapping

Bionano Genomics, Inc. Announces Resignation of Richard Shippy as Chief Business Officer

Bionano Genomics, Inc. Appoints Donna Polizio as Global Head of Market Access

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.074 loss in 3Q 2021)

Bionano Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Bionano Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Bionano Genomics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Hamilton and Bionano Genomics, Inc. Announce Commercial Availability of World's First Ultra High Molecular Weight DNA Extraction Automation Solution for OGM

Bionano Genomics Announces Publication of Study from Sorbonne Université Showing That WGS Identified Only 63% of Structural Variations That OGM Detected in Liver Cancer

Bionano Genomics Announces Launch of CLIA-Certified Bionano Laboratories

Bionano Genomics, Inc. Announces Publication of Study Using OGM for Detection of Balanced Chromosomal Rearrangements Found in Recurrent Pregnancy Loss

Bionano Genomics Announces Publication of Study Demonstrating Utility of OGM as Part of Comprehensive Workflow for Quality Evaluation of Human Induced Pluripotent Stem Cells

Bionano Genomics, Inc. Announces the First Publication Using OGM to Analyze Impact of Chromothripsis and TP53 Abnormalities on Chronic Lymphocytic Leukemia (CLL) Patients with High Genomic Complexity

Bionano Genomics Announces First Publication Using Ogm for Detection of Repeat Expansions in Canvas and Adult-Onset Ataxia

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.067 loss in 2Q 2021)

Bionano Genomics, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Bionano Genomics, Inc. Announces Publication of Research Study in Myelodysplastic Syndrome

Bionano Genomics, Inc. Announces Publication of a New Study Using OGM to Investigate Chromosome Instability During Culture of Induced Pluripotent Stem Cells

Bionano Genomics, Inc. Announces Publication of a New Study Using OGM to Investigate Inversions that May Lead to Genetic Disorders

Bionano Genomics, Inc. Reports First Published Study of OGM in Pediatric AML Shows OGM Identifies MRD Markers and Other Novel Variants That Can Impact Case Management

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.038 loss in 1Q 2021)

High number of new directors

Bionano Genomics, Inc. Announces Release of Version 6.2 of Its NxClinical Software with Significant New Capabilities for Cancer Research Applications Including HRD Analysis

Bionano Genomics Announces Publication of A New Study Using OGM Combined with Multiple Analytical Methods Including Single-Cell Analysis as a Comprehensive Molecular Strategy to Characterize the Genomic Variation in B-Cell Acute Lymphoblastic Leukemia

High number of new directors

Forecast to breakeven in 2024

Bionano Genomics, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

High number of new directors